Arrhythmia Research Technology‘s (NYSE:HRT) Signal-Averaged Electrocardiography device is 1 of only 2 ECG tests that can predict ventricular arrhythmias in patients with prior heart attacks, data from an NIH-funded multi-center clinical trial proves.
HRS13: Endosense’s force-sensing ablation catheter
Geneva-based Endosense’s proprietary contact force technology improves efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, according to new study data released last week at the annual Heart Rhythm Society meeting.
HRS2013: Sorin’s dual-chamber ICDs boast lower inappropriate shock rates
Patients with Sorin Group (BIT:SRN) dual-chamber implantable cardioverter defibrillators had significantly fewer inappropriate shocks than patients with standard single-chamber devices, according to new clinical data.
HRS2013: Boston Scientific touts battery life data
Recent study data proves longer battery life of Boston Scientific‘s (NYSE:BSX) implantable cardiac defibrillators and cardiac resynchronization therapy defibrillators, helping keep patients out of the hospital and reduce risk of infections and complications, the company claimed last week.
HRS13: Medtronic to seek expanded CRT indication on biventricular pacing data
HRS 2013 pre-meeting reflections
This morning I sit quietly in my hotel room, contemplating the day ahead at the 2013 Heart Rhythm Society Scientific Sessions in Denver. Emotions clash.
HRS 2013: St. Jude Medical touts independent safety data for next-gen Durata leads
Medical device giant St. Jude Medical (NYSE:STJ) landed an important win today after a research team released study results finding that the company’s Durata defibrillator leads proved safe and reliable in an independent review.